ReviewNature reviews. Neurology2015
Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.
Review in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04664647 (The Clinical Features of Combined Central and Peripheral Demyelination), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Clinical Features of Combined Central and Peripheral Demyelination
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Neurological manifestations of COVID-19: a retrospective observational study based on 1060 patients with a narrative review.Acta radiologica (Stockholm, Sweden : 1987) · 2023Pooled it
- Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2022Pooled it
- Efficacy and safety of anti-CD20 monoclonal antibody therapy for autoimmune nodopathies: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Anti-GLDN antibody-associated CIDP (nodopathy): transient IVIg response and B-cell depletion remission.BMC neurology · 2026Article
- Autoimmune nodopathy and focal segmental glomerulosclerosis mediated by anti-NF186 antibody: a case report and literature review.BMC neurology · 2026Review
- Case report: Unilateral optic atrophy and intracranial hypertension in anti-NF155 nodopathy: a case managed with sequential efgartigimod and rituximab.Frontiers in immunology · 2026Article
- Article
- Extracellular Vesicles-in-Hydrogel (EViH) targeting pathophysiology for tissue repair.Bioactive materials · 2025Review
- Co-occurrence of Charcot-Marie-Tooth disease type 2A and multiple sclerosis: A case report.SAGE open medical case reports · 2025Article
- The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Super-resolution of nodal and paranodal disruption in anti-pan-neurofascin-associated autoimmune nodopathy.Frontiers in immunology · 2025Article
- Axons compensate for biophysical constraints of variable size to uniformize their action potentials.PLoS biology · 2024Article
- Antibody-Mediated Nodo- and Paranodopathies.Journal of clinical medicine · 2024Review
- MuSK Myasthenia Gravis-Potential Pathomechanisms and Treatment Directed against Specific Targets.Cells · 2024Review
- Recurrent CNTN1 antibody-positive nodopathy: a case report and literature review.Frontiers in immunology · 2024Review
- Exploring the depths of IgG4: insights into autoimmunity and novel treatments.Frontiers in immunology · 2024Review
- Growing Spectrum of Autoimmune Nodopathies.Current neurology and neuroscience reports · 2023Review
- Single-cell analysis reveals novel clonally expanded monocytes associated with IL1β-IL1R2 pair in acute inflammatory demyelinating polyneuropathy.Scientific reports · 2023Article
- Value of Antibody Determinations in Chronic Dysimmune Neuropathies.Brain sciences · 2022Review
- Structural insights into the contactin 1 - neurofascin 155 adhesion complex.Nature communications · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence suggests that autoantibodies contribute to the pathogenesis of demyelination in the PNS and CNS. Rapid reversal of electrophysiological blockade after plasmapheresis or intravenous immunoglobulin treatment for acute or chronic inflammatory demyelinating polyneuropathy is more likely to result from removal or neutralization of an antibody that impairs saltatory conduction than from remyelination. Although up to 30% of patients with acute or chronic inflammatory demyelinating polyneuropathy harbour autoantibodies, specific antigens have been identified in no more than 13% of cases. To date, autoantigens identified at the node of Ranvier include neurofascin 186, gliomedin and possibly moesin in the nodal domain, and contactin-1, Caspr1 and neurofascin 155 in the paranodal domain. In some patients with multiple sclerosis, paranodal CNPase and juxtaparanodal contactin-2 trigger a humoral response. This Review explores the molecular anatomy of the node of Ranvier, focusing on proteins with extracellular domains that could serve as antigens. The clinical implications of node-specific antibody responses are addressed, and the best approaches to identify antibodies that target nodal proteins are highlighted. Also discussed are the roles of these antibodies as either secondary, disease-exacerbating responses, or as a primary effector mechanism that defines demyelination or axonal degeneration at the node, identifies disease subtypes or determines response to treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.